ACR: Biologics Prove Ineffective for Lupus
Monday, November 3, 2008
SAN FRANCISCO, Oct. 29 – Two biologics tried off-label for systemic lupus erythematosus failed to meet any endpoints in randomized trials, researchers reported here.
Neither rituximab (Rituxan) nor abatacept (Orencia) improved any primary or secondary endpoint, reported Joan T. Merrill, M.D., of the University of Oklahoma in Oklahoma City, and colleagues at the American College of Rheumatology meeting.
On the go?
Text INFO to 50555 and opt-in to receive breaking news about lupus on your mobile phone.
Message and Data Rates May Apply. Text STOP to 50555 to STOP. Text HELP to 50555 for HELP. Full Terms